STEMMED, LTD

Biotech · Private

Small-molecule STAT3 inhibitor (C188-9) to treat chronic kidney disease-induced muscle wasting by blocking myostatin expression.

Grants
$385K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease$215,557
Federal grantDepartment of Health and Human Services · Phase II · Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease$169,159
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2690LAB11 THERAPEUTICS INC.——
2691SD NANOSCIENCES, INC.——
2692OOMNI, INC.——
2693STEMMED, LTD——
2694Sangamo Therapeutics——
2695ARMA BIO, INC.——
2696IGE THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.